Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lexeo Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Lexeo Therapeutics, Inc.’s stock price such as:

• Lexeo Therapeutics, Inc.’s current stock price and volume
• Why Lexeo Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for LXEO from analysts
• LXEO’s stock price momentum as measured by its relative strength

About Lexeo Therapeutics, Inc. (LXEO)

Before we jump into Lexeo Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Want to learn more about Lexeo Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lexeo Therapeutics, Inc..

Lexeo Therapeutics, Inc.’s Stock Price as of Market Close

As of November 25, 2025, 4:00 PM, CST, Lexeo Therapeutics, Inc.’s stock price was $9.720.

Lexeo Therapeutics, Inc. is down 2.7% from its previous closing price of $9.990.

During the last market session, Lexeo Therapeutics, Inc.’s stock traded between $9.605 and $10.110. Currently, there are approximately 60.98 million shares outstanding for Lexeo Therapeutics, Inc..

Lexeo Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lexeo Therapeutics, Inc. Stock Price History

Lexeo Therapeutics, Inc.’s (LXEO) price is currently down 2.9% so far this month.

During the month of November, Lexeo Therapeutics, Inc.’s stock price has reached a high of $10.110 and a low of $7.660.

Over the last year, Lexeo Therapeutics, Inc. has hit prices as high as $10.380 and as low as $1.450. Year to date, Lexeo Therapeutics, Inc.’s stock is up 47.72%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lexeo Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 24, 2025, there were analysts who downgraded Lexeo Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Lexeo Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lexeo Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lexeo Therapeutics, Inc. (LXEO) by visiting AAII Stock Evaluator.

Relative Price Strength of Lexeo Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 24, 2025, Lexeo Therapeutics, Inc. has a weighted four-quarter relative price strength of 39.55%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Lexeo Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lexeo Therapeutics, Inc. Stock Price: Bottom Line

As of November 25, 2025, Lexeo Therapeutics, Inc.’s stock price is $9.720, which is down 2.7% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lexeo Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.